Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature

BACKGROUND: Immune checkpoint inhibitor therapy has changed the standard drug therapy for relapsed or advanced non-small cell lung cancer; its efficacy is well-recognized by pulmonary physicians, oncologists, and thoracic surgeons. Nivolumab, one of the anti-programmed cell death 1 antibodies, was t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Med Case Rep
Autors principals: Hasegawa, Takeo, Ozaki, Yuki, Inoue, Takuya, Watanabe, Yuzuru, Fukuhara, Mitsuro, Yamaura, Takumi, Muto, Satoshi, Okabe, Naoyuki, Higuchi, Mitsunori, Shio, Yutaka, Suzuki, Hiroyuki
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6813076/
https://ncbi.nlm.nih.gov/pubmed/31647029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13256-019-2245-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars